- Home
- ACON vs PPCB Comparison
ACON vs PPCB Comparison
Compare ACON & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACON | PPCB |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | Australia |
| Employees | 6 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACON | PPCB |
|---|---|---|
| Price | $3.22 | $0.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 69.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $71.77 | N/A |
| Revenue Next Year | $80.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.11 |
| 52 Week High | $21.31 | $10.69 |
Technical Indicators
Market Signals| Indicator | ACON | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 29.86 |
| Support Level | $2.38 | N/A |
| Resistance Level | $7.84 | $0.40 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 73.27 | 16.45 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.